Countdown toNOPAIN Act:
Days
ASP+6% reimbursement for EXPAREL effective January 1, 2025, when billing with code J0666 across all outpatient surgical settings
Learn more about our therapies by selecting a product below.
ProductsEXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.*
The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal.
Proprietary multivesicular liposome (pMVL) technology encapsulates drugs, preserving their molecular structure, and releases them over a desired period of time.
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is the first and only approved treatment for osteoarthritis (OA) knee pain utilizing extended-release microsphere technology.
Effective January 1, 2025
NOPAIN Act provides expanded reimbursement for EXPAREL® (bupivacaine liposome injectable suspension)1
ASP+6% CMS reimbursement when billing EXPAREL with new code J0666 across outpatient settings2,3*
*For dates of service prior to January 1, 2025, Medicare reimbursement is available in ASCs when billing with C9290. For commercial or Medicare Advantage plans, please confirm with the individual payer.3
ASP+6% = reimbursement of 106% of the average sales price.
ASC, ambulatory surgical center; CMS, Centers for Medicare & Medicaid Services; NOPAIN, Non-Opioids Prevent Addiction in the Nation.
References: 1. Consolidated Appropriations Act 2023. Accessed October 30, 2024. https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf; 2. CMS.gov. Medicare part B drug average sales price. Updated April 2, 2024. October 30, 2024. https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price; 3. CMS.gov. Published October 10, 2024. Accessed October 30, 2024. https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-3-2024-drugs-and-biologicals-posted-10-02-2024.pdf
